Abstract There are currently no nationwide epidemiological data on fungal infections in Canada. We estimated the burden of serious fungal diseases using literature review and modeling, as per a methodology previously described by the LIFE program
Introduction
Canada is a high-income country with a gross domestic product of 1551 billion dollars (USD) in 2015 (GDP per capita, 43, 249) . Several studies have examined the epidemiology of fungal infections in Canada, but most were local (single-centered, regional, or provincial) and focused on individual infections in specific populations. A single study reported on the burden of invasive fungal infections at the national level; however, these data are over 20 years old [1] and relied largely on clinical microbiology laboratory records review. Since that time, the Canadian population has expanded by 26%; use of immunosuppressive therapies that increase the risk of fungal infection have risen in importance, e.g., solid organ and stem cell transplantation and immunosuppressive biologic therapies; fungal diagnostics have improved; and medical care practices have evolved greatly. Hence, we sought to provide an estimate of the national burden of serious fungal infections.
Materials and methods
The current study targeted serious fungal infections, which were defined as fungal-associated syndromes (infection or hypersensitivity) causing significant morbidity or mortality. The LIFE methodology (http://www.LIFE-worldwide.org) was followed as described previously [2, 3] , with some modifications.
In brief, an annual burden was estimated for each targeted serious fungal disease and presented as: (i) absolute number of cases per year in Canada (representing either incident or prevalent cases, depending on the nature of the infection) and (ii) annual rates (incidence or prevalence), using the annual number of cases as the numerator and the entire Canadian population as the denominator. For simplicity, the 2014 Canadian population (n = 35,540,419 [4] ) was used regardless of the year from which the numerator data originated. To calculate the absolute number of cases per year in Canada, data derived from various sources were aggregated in a step-wise hierarchic fashion, starting with notifiable fungal diseases obtained directly from national and provincial public health agencies, followed by local data from individual centers or health authorities cited in peer review or gray literature and extrapolated to the total Canadian population (with the exception of geographically confined infections, Cryptococcus gattii, and endemic mycoses) and, finally, extrapolations from other countries' estimates.
Sources included: Statistics Canada (total and adult female population [4] , asthma prevalence [5] ), the Canadian Cancer Society (acute leukemia [6] and overall cancer incidence [7] ), the Canadian Institute for Health Information (number of solid organ transplants) [8] [10] , the World Health Organization (pulmonary tuberculosis incidence) [11] , and Cystic Fibrosis Canada (cystic fibrosis prevalence) [12] . Of note, AIDS cases from the province of Québec are not currently reported to the Public Health Agency of Canada, so the number was estimated at pro rata of the Québec population, assuming the same incidence as the rest of the country.
A map showing the geographic distribution of endemic mycoses was created using SmartDraw (SmartDraw Software, LLC, San Diego, CA, USA).
Results and discussion
Estimated annual numbers of cases of serious fungal diseases and the corresponding population rates are summarized in Table 1 . The distribution of geographically confined mycoses is shown in Fig. 1 .
Opportunistic invasive fungal infections
The burden of invasive candidiasis (IC) was extrapolated from data reported from the Calgary health region and the Province of Québec [13, 14] . In the first study, candidemia incidence was estimated at 2.8 cases per 100,000 person-years over a 5-year period, based on blood and cerebrospinal fluid culture (approximately 93% of cases were candidemia). Of note, the incidence was significantly higher (3.7/100,000) during the latter 3 years of the study. In the second study, the reported annual incidence of candidemia was 3 cases per 100,000 population, with 50% of cases arising from intensive care units. These rates translate to at least 1034 cases of candidemia each year in Canada. Deep-seated Candida infections such as peritonitis and endophthalmitis are accompanied by positive blood cultures in, at most, 50% of cases [15] . This observation is consistent with a recent nationwide German study which reported that the incidence of IC without candidemia was the same as candidemia [3] . Applying this ratio, a total of 2068 IC cases are estimated to occur annually in Canada.
Invasive aspergillosis (IA) was largely reported in the main high-risk populations, including patients with hematologic malignancies, hematopoietic stem cell transplant (HSCT) recipients, and solid organ transplant (SOT) recipients, as well as patients with severe COPD. A recent study from a Montreal center found an incidence of 8.9% among adult acute leukemia patients (both myelogenous [AML] and lymphocytic [ALL]) [16] , consistent with other international reports [17] . There were 1215 cases of AML in Canada in 2010 [6] , corresponding to approximately 108 cases of IA that year. Since AML and ALL were reported to account for approximately 75% of IA cases occurring among patients with hematologic malignancies [18] , an additional 36 IA cases are estimated to occur in patients with other hematologic malignancies. The incidence of IA amongst patients undergoing SOT was estimated using data from a prospective North American cohort study of these populations (12-month cumulative incidence: kidney, 0.2%; liver, 0.5%; lung, 3.8%; heart, 0.8%; pancreas, 0.2%) [19] . The incidence of IA after allogeneic HSCT was estimated at 7.5% based on recent observational and interventional studies [20] [21] [22] [23] A C. gattii outbreak has been ongoing in the province of British Columbia since 1999 [26] (Fig. 1) . Between 2010 and 2013, a mean of 23 C. gattii infections per year were reported to the British Columbia Centre for Disease Control [27] . During a 2-year period (1992) (1993) (1994) prior to the C. gattii outbreak, investigators had identified 81 cases of C. neoformans disease across the country [1] . Assuming that C. gattii infections represent an increased burden of disease and that C. neoformans infection rates remain unchanged, then at least 63 cryptococcal infections are estimated to occur annually.
Endemic mycoses
Blastomycosis is endemic in the provinces of Ontario, Québec, and Manitoba (Fig. 1) . It is considered hyperendemic in an area of northwestern Ontario [28] . In the former two provinces, recently published reports suggest that a mean of 44 culture-proven cases occur annually [29, 30] Fig. 1 Localization of geographically confined mycoses in Canada. The colored areas represent the approximate geographic distribution of three fungal infections: light gray Cryptococcus gattii; dark gray blastomycosis; hatched blastomycosis and histoplasmosis annual incidence of at least 63 cases of blastomycosis in these three provinces and, hence, in Canada.
Histoplasmosis occurs mainly along the Saint Lawrence river valley, in Ontario and Québec (Fig. 1) . Histoplasmin reactivity studies have shown a prevalence of 9-27% in southern Québec [32] [33] [34] . The incidence of active histoplasmosis has been estimated at 27 cases per year in Canada in a study spanning the 2-year period 1992-1994 [1] .
Coccidioides immitis/posadasii is not indigenous in Canada, though cases of active coccidioidomycosis are imported. Studies have estimated that there are between 2 and 9 cases of coccidioidomycosis annually, largely in returning travelers [1, 35] .
Non-invasive pulmonary aspergillosis
Extrapolating from pulmonary tuberculosis 2014 annual incidence data (n = 1065) [11] , the prevalence of CPA following tuberculosis was estimated at 148 cases using a previously reported model [36] . If prior pulmonary tuberculosis is the predisposing factor in approximately 30% of cases of CPA [37] , an estimated 492 new cases of CPA are expected.
ABPA burden was derived from the number of Canadian adults with asthma (n = 2,444,804) [5] and the number of patients suffering from cystic fibrosis (CF; n = 4077) [12] . The proportion of ABPA among asthma patients was estimated at 2.5% [38] and 18% in those with CF [39] , leading to a calculated national prevalence of 61,854 cases of ABPA. SAFS burden was derived from asthma prevalence and estimated at 73,344 cases, assuming a severe asthma prevalence of 10% of all cases of asthma and an Aspergillus sensitization prevalence of 30% [40] .
Mucosal candidiasis
Recurrent vulvovaginal candidiasis (RVVC) is reported to affect up to 9% of women of reproductive age [41] . The Canadian prevalence of RVVC was calculated by applying 6% to the Canadian adult women's population (between 15 and 50 years old; n = 8,311,477 [4] ), yielding an estimated 498,688 cases present.
In a systematic review, the prevalences of oropharyngeal candidiasis (OC) in cancer patients were estimated at 7.5%, 39.1%, and 32.6% before, during, and after the end of treatment, respectively [42] . In Canada, 196,900 new cases of cancer were estimated in 2015 [7] . Because the total number of patients undergoing treatment and the survival rates are not known, only pre-treatment OC was considered and the estimated prevalence was calculated at 14,767 cases of OC nationally. HIV infection is responsible for an additional 752 cases, including approximately 1% of HIV-positive patients without AIDS and 18% of those with AIDS [43] , based on a prevalence of 71,300 HIV-positive patients in 2013 in Canada, including 218 with AIDS [10] .
Esophageal candidiasis (EC) is an AIDS-defining illness affecting nearly 20% of patients with AIDS [44] ; thus, at least 43 cases of EC are expected to occur annually in Canada. EC is also associated with other underlying conditions (e.g., receipt of corticosteroids), but data on infection rates in these populations are not sufficient to inform accurate estimates.
Our study found that approximately 3000 invasive fungal infections occur annually in Canada, while over half a million people suffer from a chronic Candida or Aspergillus infection. Overall, RVVC is likely the most frequent serious fungal disease in Canada, with substantial quality of life impairment [45] and health costs [46] , prompting the need for specific guidelines addressing diagnostics and treatment. Education on current guidelines for non-invasive forms of pulmonary aspergillosis is needed to increase awareness, diagnosis, and treatment proficiency among healthcare providers. Invasive fungal infections annual incidence (8.3/100,000) is similar to that of invasive pneumococcal disease (8.9 in 2014) and higher than invasive Streptococcus pyogenes disease (4.7 in 2013), infectious syphilis (5.1 in 2011), tuberculosis (4.4 in 2014), and HIV (5.9 in 2013), all regarded as important infectious diseases in Canada [47] . Amongst invasive infections, candidiasis is by far the most common disease, followed by aspergillosis. Cryptococcosis, pneumocystosis, and endemic mycoses are less commonly encountered, consistent with findings of a recent large registry across North America [48] . Invasive fungal infections data from two Canadian centers have confirmed 90-day fatality rates of 41% and 36% for IC and IA, respectively [49] , representing over a thousand deaths annually in Canada.
Our estimates of serious fungal infection burden in Canada provide an opportunity for both healthcare providers and public health agencies to improve diagnostics, surveillance, and formal epidemiological studies, including measures of healthcare utilization.
